Use access key #2 to skip to page content.

Closing CYTR (CytRx) underperform

Recs

1

April 11, 2008 – Comments (0)

It's a little hard to figure out whether the decline in price was related more to the arimoclomol clinical hold, the small cap biotech swoon, or the RXi spinoff. Either way, there's not a lot to keep driving the price down and a lot of things that could send it back up. The FDA could lift the clinical hold, small cap biotech will likely recover quickly once market liquidity improves, and a strong performance from RXi will continue to benefit CytRx.

0 Comments – Post Your Own

Featured Broker Partners


Advertisement